Risk of recurrence of hepatocellular carcinoma in patients treated with interferon-free antivirals
Gastroenterol Hepatol. 2019 Oct;42(8):502-511.
doi: 10.1016/j.gastrohep.2019.05.003.
Epub 2019 Aug 28.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Aparato Digestivo, Hospital San Pedro, Logroño, La Rioja, España; Grupo BCLC, Unidad de Oncología Hepática, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Universidad de Barcelona, Barcelona, España.
- 2 Grupo BCLC, Unidad de Oncología Hepática, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Universidad de Barcelona, Barcelona, España.
- 3 Grupo BCLC, Unidad de Oncología Hepática, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Universidad de Barcelona, Barcelona, España. Electronic address: MREIG1@clinic.ub.es.
Abstract
Eradication of the hepatitis C virus (HCV) with interferon-free therapies (DAAs) has modified the course of the disease, as the rate of patients with compensated cirrhosis who achieve a sustained virological response exceeds 95%. However, the impact on development of hepatocellular carcinoma (HCC) is currently in dispute. This argument could be divided into different key points: the impact of DAA on rate of HCC recurrence, the temporal link between starting DAAs and HCC recurrence, and finally, the aggressive pattern of HCC. Therefore, the aim of this review is to analyse the available results in this population of patients from a clinical perspective where the risks and benefits of HCV eradication with DAA therapies are evaluated in patients with complete response of HCC.
Keywords:
AAD; Carcinoma hepatocelular; DAA; HCV; Hepatocellular carcinoma; Interferon-free; Libre interferón; Recurrence; Recurrencia; VHC.
Copyright © 2019. Publicado por Elsevier España, S.L.U.
MeSH terms
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use*
-
Carcinoma, Hepatocellular / etiology
-
Carcinoma, Hepatocellular / pathology*
-
Carcinoma, Hepatocellular / therapy
-
Carcinoma, Hepatocellular / virology
-
Disease Progression
-
Embolization, Therapeutic
-
Hepatectomy
-
Hepatitis C, Chronic / complications
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Interferons
-
Liver Neoplasms / etiology
-
Liver Neoplasms / pathology*
-
Liver Neoplasms / therapy
-
Liver Neoplasms / virology
-
Neoplasm Recurrence, Local / epidemiology
-
Neoplasm Recurrence, Local / etiology*
-
Neoplasm Recurrence, Local / prevention & control
-
Prospective Studies
-
Retrospective Studies
Substances
-
Antiviral Agents
-
Interferons